参考文献/References:
[1]杨建平,管圣,唐加热克,等.TIPS联合PMT在复杂性门静脉血栓中的应用[J].新疆医学,2020,50(3):277-280.[2]刘金芝,胡乃中,许建明.肝硬化合并门静脉血栓形成危险因素及预后研究[J].安徽医科大学学报,2016,51(2):280-283.[3]热那特·克力木,吐尔干艾力·阿吉,邵英梅.肝硬化并发门静脉血栓患者临床特征及其危险因素分析[J].实用肝脏病杂志,2020,23(3):401-404.[4]韩东,彭经纬,谢辉晋.脾切除联合贲门周围血管离断术治疗肝硬化门脉高压症患者预防门静脉血栓形成研究[J].实用肝脏病杂志,2020,23(3):409-412.[5]田真真.肝硬化静脉曲张出血患者临床内镜特征及再出血的危险因素研究[J].淮海医药,2020,38(2):136-139.[6]宋子敏,徐锋,杨纯博,等.肝硬化门静脉高压症脾切除术后门静脉系统血栓形成相关因素分析[J].中华普通外科学文献(电子版),2020,14(3):184-188.[7]Valla DC.Recent developments in the field of vascular liver diseases[J].Liver Int,2020,40(Suppl 1):142-148.[8]Scheiner B,Northup PG,Gruber AB,et al.The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease[J].Liver Int,2020,40(6):1415-1426.[9]Eshraghian A,Nikeghbalian S,Kazemi K,et al.Portal vein thrombosis in patients with liver cirrhosis and its impact on early and long-term outcomes after liver transplantation[J].Int J Clin Pract,2018:e13309.[10]Tsuchimoto Y,Asai A,Okamoto N,et al.Tu1713 the short duration until the start of treatment for portal vein thrombosis in patients with livers cirrhosis,improve their survival rate through the reduction foe the size of the thrombus[J].Elsevier Inc,2020,158(6):S-1-S-1603.[11]Qi X,De Stefano V,Li H,et al.Anticoagulation for the treatment of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis of observational studies[J].Eur J Intern Med,2015,26(1):23-29.[12]Acuna-Villaorduna A,Tran V,Gonzalez-Lugo JD,et al.Natural history and clinical outcomes in patients with portal vein thrombosis by etiology: A retrospective cohort study[J].Thromb Res,2019(174):137-140.[13]张振,王孟龙,张海涛,等.肝硬化门静脉高压患者脾切除断流术后早期门静脉血栓形成的因素及预防性活血、抗凝、祛聚治疗的效果[J].肝脏,2019,24(1):24-27,89.[14]阮芳鸣,李弼民.肝硬化门静脉血栓形成的危险因素[J].临床肝胆病杂志,2020,36(1):182-185.[15]赵平,黎涛,谢吉良,等.早期抗凝干预用于经颈静脉肝内门体静脉支架分流术联合PSE治疗肝硬化患者价值探讨[J].实用肝脏病杂志,2020,23(1):82-85.[16]郑桂茹,金俊华,方杨丽,等.乙型肝炎肝硬化患者凝血参数、门脉血流动力学参数与门静脉血栓发生的关系分析[J].现代实用医学,2020,32(3):307-309.[17]赵静,王慧超,葛相栓,等.生长抑素治疗肝硬化并发门静脉血栓的临床研究[J].航空航天医学杂志,2020,31(2):142-144.[18]张德成.肝硬化门静脉血栓形成危险因素和抗凝治疗的疗效分析[D].安徽医科大学,2018.[19]王朝阳,段晓怡,李丹,等.TIPS联合搅拌溶栓治疗肝硬化急性门静脉血栓的临床疗效分析[J].中华肝胆外科杂志,2020(1):22-26.[20]张文广,任建庄,韩新巍,等.经颈静脉肝内门体分流术联合AngioJet血栓清除装置治疗肝硬化急性门静脉广泛血栓效果分析[J].中华医学杂志,2020(7):533-537.[21]陆申新,陈世耀.抗凝治疗肝硬化患者并发门静脉血栓的循证医学证据[J].实用肝脏病杂志,2016,19(5):624-628.[22]李卿,呼奇轩,王丽林.肝硬化合并门静脉血栓患者应用低分子肝素钠抗凝的临床价值分析[J].现代消化及介入诊疗,2019,24(10):1137-1139.[23]Hernández-Conde M,Llop E,Fernández-Carrillo C,et al.Visceral fat is associated with cirrhotic portal vein thrombosis[J].Expert Rev Gastroenterol Hepatol,2019,13(10):1017-1022.[24]Noronha Ferreira C,Reis D,Cortez-Pinto H,et al.Anticoagulation in Cirrhosis and Portal Vein Thrombosis Is Safe and Improves Prognosis in Advanced Cirrhosis[J].Dig Dis Sci,2019,64(9):2671-2683.[25]贾昊宇,杨长青.肝硬化患者门静脉血栓的诊断与治疗[J].肝脏,2019,24(9):984-985.[26]吕靖,董思思,顾宏图,等.肝硬化并发门静脉血栓的危险因素及中医证候特点[J].临床肝胆病杂志,2019,35(10):2210-2213.[27]陈仙艳.肝硬化合并上消化道出血患者门静脉血栓形成危险因素分析与护理[J].护理实践与研究,2019,16(18):13-15.[28]李志英,雷霞,欧阳卫泽,等.肝硬化上消化道出血患者并发门静脉血栓形成的危险因素分析[J].中国医学创新,2019,16(27):128-131.[29]徐祺林,郝少欢,冉博.肝硬化脾切除术后门静脉系统血栓形成的危险因素分析[J].实用肝脏病杂志,2019,22(5):708-711.[30]曾钗明,郭太林,陈建康,等.肝硬化联合门静脉血栓形成的危险因素及预后效果[J].血管与腔内血管外科杂志,2019,5(5):407-410,430.